Dapagliflozin for diabetes, kidney disease, and inflammation
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests if a once-daily medication called dapagliflozin (Forxiga) can reduce inflammation and improve iron use and red blood cell production in people with both type 2 diabetes and chronic kidney disease. It may help protect your kidneys and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old and have been diagnosed with type 2 diabetes.
- Your kidney function (measured by eGFR) must be between 20 and 80 mL/min/1.73 m², meaning moderate kidney damage.
- A urine test must show a certain amount of protein (albumin) ranging from 30 to 3500 mg/g.
- Your average blood sugar over the last 3 months (HbA1c) should be between 7.0% and 11.0%.
- You cannot have type 1 diabetes, kidney disease from other causes, or hemoglobin level below 9 g/dL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This study tests if dapagliflozin (a medication for diabetes and kidney health) can help prevent kidney injury in people with type 1 diabetes. It is for adults aged 18 to 64 who have moderately reduced kidney function and some protein in their urine.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.